Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Predictive Biological Markers for Response of Invasive Breast Cancer to Anthracycline / Cyclophosphamide-based Primary (Radio-)Chemotherapy

HANS-BERND PRISACK, CHRISTIAAN KARREMAN, OLGA MODLICH, WERNER AUDRETSCH, MAHMOUD DANAE, MAHADI REZAI and HANS BOJAR
Anticancer Research November 2005, 25 (6C) 4615-4621;
HANS-BERND PRISACK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Hans-Bernd.Prisack@uni-duesseldorf.de
CHRISTIAAN KARREMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OLGA MODLICH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WERNER AUDRETSCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAHMOUD DANAE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAHADI REZAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANS BOJAR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The role of biological markers for the prediction of neoadjuvant chemotherapy and radio-chemotherapy may be evaluated using pathological complete response [pCR] in patients with invasive breast cancer. Materials and Methods: To investigate this, pre-treatment biopsies from 517 patients with locally advanced breast cancer were analyzed for expression of estrogen receptor [ER], progesterone receptor [PgR], Her-2/neu, epidermal growth factor receptor [EGF-R], p53, Bcl-2 and MIB-1 by immunohistochemistry [IHC], and these data were compared to the pathological response after preoperative epirubicine/cyclophosphamide [EC] chemotherapy (+/- radiotherapy). Results: pCR was more frequent (28.3%, 56/198) in tumors that received radio-chemotherapy compared to chemotherapy alone (11.9%, 38/319, p<0.0001). Patients with high grading, lower ER, PgR, Bcl-2 or a higher proliferation had a significantly greater benefit from chemotherapy. The overexpressions of Her2/neu or EGF-R were weakly correlated to pCR, while p53 staining did not have any predictive value. Younger patients, with negative PgR and high proliferation index, had the highest benefit from EC therapy (56% pCR). The different multivariate indices of binary regression, PLS-DA and SIMCA, had similar predictive quality and were slightly superior to univariate factors. Conclusion: This study emphasizes the value of traditional biological markers and Bcl-2 for use in the individual selection of a primary therapy regimen.

  • ERα
  • PgR
  • proliferation
  • Bcl-2
  • Her-2/neu
  • p53
  • EGF-R

Footnotes

  • Received April 12, 2005.
  • Accepted July 1, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (6C)
Anticancer Research
Vol. 25, Issue 6C
1 Nov 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictive Biological Markers for Response of Invasive Breast Cancer to Anthracycline / Cyclophosphamide-based Primary (Radio-)Chemotherapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Predictive Biological Markers for Response of Invasive Breast Cancer to Anthracycline / Cyclophosphamide-based Primary (Radio-)Chemotherapy
HANS-BERND PRISACK, CHRISTIAAN KARREMAN, OLGA MODLICH, WERNER AUDRETSCH, MAHMOUD DANAE, MAHADI REZAI, HANS BOJAR
Anticancer Research Nov 2005, 25 (6C) 4615-4621;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Predictive Biological Markers for Response of Invasive Breast Cancer to Anthracycline / Cyclophosphamide-based Primary (Radio-)Chemotherapy
HANS-BERND PRISACK, CHRISTIAAN KARREMAN, OLGA MODLICH, WERNER AUDRETSCH, MAHMOUD DANAE, MAHADI REZAI, HANS BOJAR
Anticancer Research Nov 2005, 25 (6C) 4615-4621;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival
  • Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy
  • Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire